Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
ESMO Conference 5-8 July 2007, Lugano, Switzerland - Press Program
July 22nd, 2007
Hormone inhibitor promising for hard-to-treat prostate cancer For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials. Two poster to be presented at the ESMO Conference Lugano (ECLU) show the drug results. Analysis confirms benefits of combining trastuzumab and chemotherapy in Breast cancer An analysis of five major breast cancer trials has confirmed that combination treatment with the antibody treatment trastuzumab and chemotherapy improves survival in women with...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
